Search the Newsreel

KIOCL revenue rises 67% in Q1FY27, but net loss widens to ₹155 crore

Tokio Marine (TSE:8766) Stock Sees Profit Reset As Margin Pressure Persists

IKIO Technologies Q1 Results: Conference call audio released for investors

IKIO Tech Standalone June 2026 Net Sales at Rs 44.84 crore, up 15.9% Y-o-Y

IKIO Technologies profit surges 365% in Q1FY27 on diversified growth

Kiora Pharmaceuticals (KPRX) reports 9.99% stake held by Perceptive group

Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have reported a beneficial ownership of 9.99% in Kiora Pharmaceuticals, Inc. This updated Schedule 13G filing corrects a previous submission made under an incorrect Central Index Key (CIK). The report details the …

KIOCL Share Price Target 2027, 2028 and 2030: Long Term Analyst Forecast

IKIO Technologies Limited Reports Earnings Results for the First Quarter Ended June 30, 2026

Form 8K Kiora Pharmaceuticals Inc For: 7 August By Investing.com

This article announces that Kiora Pharmaceuticals Inc. filed a Form 8K on August 7th. The brief piece includes the stock symbol KPRX and a mention of its stock performance, rising 3.13%. It also includes general market data and related news.

KPRX|Kiora Pharmaceuticals Inc|Price:2.640|Chg%:+0.080

Kiora Pharmaceuticals Inc (KPRX) stock is currently trading at $2.640, up 3.13% with a market capitalization of $9.93M. The company is a clinical-stage pharmaceutical firm focused on developing therapies for retinal diseases, including KIO-301 for inherited and age-related degenerative retinal diseases, and KIO-104 for …

Kiora Starts Enrollment in 100-Microgram Retinitis Pigmentosa Cohort

Kiora Pharmaceuticals reported its second-quarter 2026 financial results, highlighting approximately $16.8 million in cash and short-term investments, which is expected to fund operations into late 2028. The company is advancing enrollment in higher-dose cohorts for its Phase 2 ABACUS-2 trial (KIO-301 for retinitis pigmentosa) …

Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Kiora Pharmaceuticals reported its second-quarter 2026 financial results, highlighting advancements in its Phase 2 ABACUS-2 clinical trial for KIO-301 and the KLARITY trial for KIO-104. The company ended the quarter with $16.8 million in cash and short-term investments, providing an operating runway into late …

Kiora Pharmaceuticals (KPRX) Gains 2.83% as Shares Approach $2.67 Resistance - Gap and Reverse

IKIO Technologies to host Q1FY27 earnings call on Aug 11

KIOCL appoints three non-official independent directors

Price to sales forward of Kiora Pharmaceuticals, Inc. – NASDAQ:KPRX

The article provides a financial overview of Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) focusing on its price to sales forward metric. It is a data point from TradingView, indicating financial analysis for the pharmaceutical company.

Kioxia’s outlook miss clouds optimism about memory chip boom

Japan's Kioxia forecasts 31-fold profit surge as tech shares swing

Kiora Pharmaceuticals Inc (KPRX) Financial Health: Profitability & Balance Sheet Analysis

This article provides a financial health analysis of Kiora Pharmaceuticals Inc (KPRX), noting its current financial score of 6.23, ranking 275 out of 385 in the Biotechnology & Medical Research industry. The company's financial status is stable, but its operating efficiency is low. Key …

Kiora Pharmaceuticals Inc (KPRX) Institutional Confidence

This article provides an "Institutional Confidence" report for Kiora Pharmaceuticals Inc (KPRX) as of July 28, 2026. It details the institutional shareholdings and recent changes in holdings for several firms and individuals. Notable changes include Lincoln Park Capital, LLC increasing holdings by over 600% …

Lower iron ore prices hit Kumba earnings

Tokio Marine Holdings Number of Employees 2026 | Employee Count & Headcount Data

Kumba Iron Ore Ltd (KIROY) (Q2 2026) Earnings Call Highlights: Navigating Challenges and ...

This article first appeared on GuruFocus. Revenue: Impacted by a stronger exchange rate and higher input costs, leading to lower EBITDA. Interim Cash Dividend: R2.5 billion declared, with an additional R0.5 billion to empowerment partners. Realized Iron Ore Price: $90 per ton, down from …

Kiora Pharmaceuticals Inc (KPRX) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Kiora Pharmaceuticals Inc (KPRX), noting its current valuation score of 8.72 within the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -0.97, which is significantly below its recent high but above its recent …

Kumba Iron Ore Publishes H1 2026 Interim Results as Anglo American Highlights Operational Insights

Kumba Iron Ore’s Profit Drops 42% on Freight, Rand and War Costs

Kumba Iron Ore Limited 2026 Q2 - Results - Earnings Call Presentation (OTCMKTS:KIROY) 2026-07-28

Will Kioxia's stock price rebound on earnings announcement? What is the true value of Japan’s 'most profitable company'? Watch for the stock split too. [Earnings Preview]

Kiora Pharmaceuticals Inc (KPRX) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides historical dividend and stock split information for Kiora Pharmaceuticals Inc (KPRX). It notes that KPRX has distributed $0.00 in dividends over the past five years. The company has undergone several merger-related stock splits, including 9-for-1 splits in June 2024 and 40-for-1 …

Kiora Pharmaceuticals Market Sentiment

This article analyzes the market sentiment for Kiora Pharmaceuticals (KPRX), detailing analyst consensus, short interest, options flow, and insider activity. It highlights a "Buy" consensus from two analysts, with an average price target of $6, and a low short interest of 0.2%. The report …

Kiora Pharmaceuticals Inc (KPRX) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Kiora Pharmaceuticals Inc (KPRX), outlining its major shareholders and institutional holdings. It provides a breakdown of shareholder types, institutional ownership trends over several quarters, and recent shareholder activity with changes in holdings for key investors.

KPRX|Kiora Pharmaceuticals Inc|Price:2.550|Chg%:+0.050

This article provides a detailed financial overview of Kiora Pharmaceuticals Inc. It includes current stock price, market capitalization, and a deep dive into the company's financial statements such as income statement, balance sheet, and cash flow statement. The report covers various financial indicators and …

Kiora Pharmaceuticals Inc (KPRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Kiora Pharmaceuticals Inc (KPRX), detailing its business segments, regional revenue, and profit contribution. The data indicates that relevant financial information for FY2025 has not yet been disclosed by the company. For the regions, only the United States …